Abstract 318P
Background
The semi-dry dot-blot (SDB) method, a diagnostic procedure for detecting lymph node (LN) metastases using anti-cytokeratin (CK) antibody, is based on the theory that epithelial components such as CK are not found in normal LNs. Thus, metastases are diagnosed on basis of the presence of CK in lavage fluid of sectioned LNs. We prospectively evaluated novel SDB kits that use a newly developed anti-CK19 antibody and an automatic reader for diagnosing sentinel LN metastases in patients with breast cancer as a multi-center study.
Methods
We obtained 924 sentinel LNs dissected between January 2021 and December 2021 at six institutes in Japan. We excluded patients with neoadjuvant chemotherapy and neoadjuvant endocrine therapy. These LNs were sliced at 2-mm intervals and washed with PBS. Cells suspended in the lavage fluid of sliced LNs were centrifuged and lysed to extract protein. The extracted protein was applied to the SDB kit to diagnose LN metastasis using an automatic reader that evaluates absorbance. Washed LNs were blindly examined using intraoperative and permanent histological examination. Diagnoses based on SDB kit were compared with diagnoses made by permanent histological examination of the LNs. Primary endpoints were sensitivity, specificity, and overall agreement of the SDB kit for distinguishing macrometastases from non-macrometastases.
Results
Ninety-four of the 924 LNs were assessed as macrometastases, 40 as micrometastases and 790 as negative by histological examination. With a borderline CK19 absorbance of 11.9 milli-absorbance for detecting macrometastases with 0.989 Area Under the Curve, the sensitivity, specificity, and overall agreement of the SDB kit were 94.7%, 98.3%, and 97.9%, respectively. Furthermore, the kits and the automatic reader yielded diagnoses in approximately 20 min at a cost of less than 30 EUR for the SDB kit and less than 3,000 EUR for the automatic reader.
Conclusions
The kits with an automatic reader used in our study were accurate, quick, and cost-effective in diagnosing LN metastases without loss of LN tissue, and were especially useful for detecting distinguish macrometastases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Japan Agency for Medical Research and Development.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
292P - Unlocking the potential of circulating miRNAs in predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis
Presenter: Paola Tiberio
Session: Poster session 02
294P - Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
Presenter: Tong Wei
Session: Poster session 02
295P - ESR1, PGR, ERBB2, MKI67 single gene analysis in neoadjuvant-treated early breast cancer patients
Presenter: Rebekks Spiller
Session: Poster session 02
296P - Identification of metabolism-related therapeutic targets to improve response to neoadjuvant chemotherapy in early breast cancers
Presenter: Françoise Derouane
Session: Poster session 02
297P - Prognostic and predictive impact of NOTCH1 in early breast cancer
Presenter: Julia Engel
Session: Poster session 02
298P - Association of luminal-androgen receptor (LAR) subtype with low HER2 in triple-negative breast cancer
Presenter: Lee Min Ji
Session: Poster session 02
299P - Single-cell transcriptomic analysis reveals specific luminal and T cell subpopulations associated with response to neoadjuvant therapy in early-stage breast cancer
Presenter: Xiaoxiao Wang
Session: Poster session 02
300P - Correlation of PD-L1 protein and mRNA expression and their prognostic impact in triple-negative breast cancer
Presenter: Kathleen Schüler
Session: Poster session 02
301P - Epigenetic modifications of IL-17 gene in patients with early breast cancer and healthy controls
Presenter: Ljubica Radmilovic Varga
Session: Poster session 02
302P - Clinicopathological features and outcomes of pregnancy associated breast cancer: Case control study -single institution experience
Presenter: Nashwa Kordy
Session: Poster session 02